Widely regarded as being “at the vanguard” of trade mark law in relation to pharma products, Roiter Zucker has achieved outstanding success litigating matters for clients within the life sciences industry. We have a reputation for winning cases dismissed by others as “hopeless.” In doing so, we push boundaries and challenge legal thinking.

We regularly advise on the interface between trade mark rights and competition issues. Our work for Dowelhurst & Medihealth in the Boehringer litigation has defined how parallel trade should be conducted within the European Union. Our work in this field is cutting-edge.